BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu Sells 500 Shares

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $200.00, for a total transaction of $100,000.00. Following the sale, the chief operating officer now owns 4,500 shares in the company, valued at $900,000. The sale was disclosed in a filing with the SEC, which is available at this link.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, September 19th, Xiaobin Wu sold 4,500 shares of BeiGene stock. The shares were sold at an average price of $200.14, for a total transaction of $900,630.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The shares were sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Trading Up 0.7 %

Shares of BeiGene stock opened at $198.59 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $215.00. The firm has a market cap of $19.24 billion, a PE ratio of -26.23 and a beta of 0.61. The company has a 50 day simple moving average of $181.25 and a two-hundred day simple moving average of $164.21.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. During the same period in the previous year, the firm posted ($3.64) EPS. The firm’s revenue was up 56.1% compared to the same quarter last year. Analysts expect that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BGNE. Citigroup upped their price target on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. JMP Securities started coverage on shares of BeiGene in a research note on Wednesday. They issued a “market outperform” rating and a $288.00 target price on the stock. Bank of America cut their price target on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.21.

Institutional Investors Weigh In On BeiGene

A number of hedge funds have recently made changes to their positions in the business. Partners Capital Investment Group LLP purchased a new position in BeiGene in the 4th quarter worth $2,762,000. Swedbank AB bought a new stake in shares of BeiGene in the 1st quarter valued at about $2,596,000. AIA Group Ltd lifted its stake in shares of BeiGene by 38.9% in the 1st quarter. AIA Group Ltd now owns 18,497 shares of the company’s stock valued at $2,893,000 after acquiring an additional 5,181 shares during the last quarter. M&G Plc purchased a new stake in BeiGene during the 1st quarter valued at about $29,649,000. Finally, Van ECK Associates Corp grew its position in BeiGene by 8.9% during the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock worth $13,636,000 after acquiring an additional 7,816 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.